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tions typically involve continuous bladder irrigation (CBI), fre-
quent platelet transfusions, and medications for symptom control.
Because effective management for HC has not been established,
other alternatives, such as the use of activated factor VII and
hyperbaric oxygen therapy, are being examined. Hyperbaric oxy-
gen therapy provides a noninvasive approach to the management
and resolution of this problematic complication. A case study will
be presented to demonstrate the necessity of further understanding
of these approaches for the treatment of HC.
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THE NURSE’S ROLE AS COORDINATOR IN THE SAFE AND EFFECTIVE
MANAGEMENT OF PATIENTS WITH COMORBIDITIES UNDERGOING AL-
LOGENEIC STEM CELL TRANSPLANTATION
Ramos, C., Cook, L., Shelburne, N., Bevans, M. National Institutes of
Health, Bethesda, MD.
Allogeneic stem cell transplantation (SCT) is an intense treat-
ment offering a potential cure for leukemia. Transplantation-re-
lated complications (TRCs), in addition to the effects of the un-
derlying disease, are common during transplantation. To avoid
secondary complications such as falls, intense monitoring by the
patient, family, and health care team are required. Blindness, a rare
but serious toxicity of leukemia and associated treatments, can
further complicate the patient’s experience during transplantation
and put him or her at increased risk for injury.
Before admission of a leukemia patient with new-onset blindness,
a team of clinical research oncology nurses recognized the unique
degree of personal, emotional, and physical dependence of this
high-risk patient. This high level of dependence required a com-
mitment by the patient, family, and health care team beyond that
normally expected. This generated a need for a unique education
plan related to the environment, activities of daily living, and
communication approaches. To develop this plan and ensure a safe
environment, the clinical research nurses used a collaborative care
model to involve the health care team. An important element in
this model was the inclusion of all disciplines involved in patient
care and community resources.
The purpose of this project is to share a collaborative care model
that improves the management of allogeneic SCT patients with
comorbidities such as blindness. The success of this model was
based on the inclusion of supportive care personnel normally
outside the transplantation team. This presentation will outline the
nurse’s role as coordinator of an expanded multidisciplinary team
in managing unique and complex patients undergoing SCT. These
include achievement of functional independence, injury preven-
tion, and improved psychological well-being for the patient and
family.
The oncology nurse is in a key position to identify the risk level
of unique patients undergoing allogeneic SCT and bring together
multiple resources, in the hospital and community, to support the
patient and family. This collaborative care model demonstrates the
effectiveness of the oncology nurses’ role as a coordinator of the
multidisciplinary team in achieving high-quality patient and family
care. This model can be applied to other high-risk cancer patients
that may be at increased risk of injury due to other comorbid
conditions as they present for SCT.
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UNDERSTANDING VENO-OCCLUSIVE DISEASE IN THE BLOOD AND
MARROW TRANSPLANTATION POPULATION: THE NURSE’S ROLE
Brandert, M., Ippoliti, C. University of Texas M.D. Anderson Cancer
Center, Houston, TX.
Veno-occlusive disease (VOD) is a serious, often fatal complica-
tion of blood and marrow transplantation (BMT). It has been
reported that VOD is the third-leading cause of transplantation-
related mortality in allogeneic patients, after graft-versus-host dis-
ease and infection. Research indicates the reported incidence of
VOD may be as high as 54%. Onset of symptoms usually occurs
within the ﬁrst 30 days posttransplantation; however, reports of
VOD occurring after day 30 have also been documented. The
diagnosis of VOD is made after other potential complications of
transplantation are ruled out. Clinical features may include ﬂuid
retention, weight gain, ascites, right upper quadrant pain, and
jaundice. Once a diagnosis of VOD is made, aggressive treatment
is necessary. Therapeutic goals are aimed at maintaining renal
perfusion and intravascular volume while limiting extravascular
ﬂuid accumulation, and inhibiting the coagulation cascade.
New therapeutic approaches to the treatment of VOD continue to
be examined. Studies using the drug deﬁbrotide have shown it to be
highly efﬁcacious, while minimizing toxicity. A case study will be
presented that reviews the use of deﬁbrotide on a matched unrelated
donor transplantation receipient diagnosed with VOD. The diagnosis
can have a major impact on the treatment and care of these patients.
Knowledge of the risk factors, pathophysiology, and clinical features
of this syndrome can assist nurses with early detection, symptom
management, supportive care, and patient and family education.
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THE EXPERIENCE OF INTENSIVE CARE UNIT FOR HEMATO-ONCOLOGY
PATIENTS
Kim, H.J., Youn, J.H., Shim, S.M., Hong, E.Y., Kim, K.S., Ban, J.Y.,
Han, S.S., Cho, H.S., Song, B.E. St. Mary’s Hospital, Catholic HSCT
Center, Seoul, Korea.
We established in intensive care unit for hemato-oncology pa-
tient since 1999. In fact, we have concerned about transfer inten-
sive care unit in spite of leukopenic status the reason why infection.
We reviewed the medical records of 310 patients, there were the
data, initial diagnosis, cause of admission and reason to ICU,
admission duration, need for mechanical ventilation and cause of
death, from January 2003 to April 2004 for 13months to identify
efﬁcacy of intensive care and further direction. The mean age was
38.9 years old, 174(56%) of them were men and 136 of them were
women. The distribution of disease was orderly AML (41.94%),
ALL 50(16.13%), CML 27(8.71%), SAA 21(6.77%), MDS
17(5.48%) and so on. The type of treatment was Chemo-therapy
102(32.9%), Post HSCT 97(31.3%). The admission duration was
8.19 days, there was no signiﬁcant between HSCT and chemo-
therapy. However, comparably HSCT group was higher than
conservative care group.
The reason for transfer to Hematology ICU was interstitial
pneumonia 88(28.38%), sepsis 76(24.52%), organ failure
61(19.68%). The mechanical ventilator care group of them was
138(44.5%). The reason of them was interstitial pneumonia
48(34.78%), sepsis 27(19.57%), organ failure 24(17.39%). The
mortality of ventilator care group was 111(80.43%, P
One hundred four patients (33.55%) of subject were improved.
Yet, 160(51.61%) were died and 46(14.84%) were hopeless dis-
charged. The direct and contributing cause of death was Multi-
organ failure 91(56.88%), sepsis 33(20.63%). The mortality of
HSCT group was 66(68%) and chemotherapy group was 49(48%).
The mortality of HSCT group was relatively higher than chemo-
therapy group. Ninety-one of Non-ventilator group were im-
proved the meaning was better than ventilator care group. There
were different of mortality compare with between Mechanical
ventilator group 111(69.37%) and Non-ventilator care group
49(30.63%).
In conclusion, we suggest that a classiﬁcation tool should be
developed to predict prognostic factor of speciﬁc hemato-oncolgy
intensive care.
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A COMPETENCY-BASED ORIENTATION TOOL FOR INITIAL ORIENTA-
TION TO THE CARE OF BLOOD AND MARROW TRANSPLANTATION
PATIENTS
Grifﬁn, J.M., Brauning, N., Kehoe, B., Poonoosamy, S. Jewish Hospital,
Cincinnati, OH.
Blood and marrow transplantation (BMT) nursing requires a
speciﬁc set of competencies to provide effective care to BMT
patients. The development of a competency-based orientation tool
(CBO) speciﬁc to BMT is one strategy to standardize the orien-
tation of nurses new to BMT. A BMT-speciﬁc CBO facilitates the
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ability of preceptors to focus on the knowledge, skills, and abilities
required in the ﬁrst year of practice on a BMT unit.
Before development of the CBO, experienced staff nurses on the
BMT unit identiﬁed a lack of consistency in novice BMT staff
nurses in performance of key BMT skills and assessments. Con-
versely, the group of novice BMT nurses identiﬁed frustration with
a lack of a consistent approach by preceptors in the teaching of key
BMT skills and assessments. In response to these concerns, a core
group of experienced BMT nurses developed a CBO speciﬁc to
BMT using an evidence-based approach.
Ten core competencies with corresponding measurable criteria
were identiﬁed for the BMT CBO. Competency veriﬁcation meth-
ods used by preceptors include observation, return demonstration,
discussion, mock events, and self-assessment by the orientee. In
addition to the CBO, a BMT skills checklist was developed for
competency validation of a core set of technical skills identiﬁed as
essential for an orientee to be deemed competent to practice in the
BMT setting. The BMT-speciﬁc CBO resulted in a signiﬁcant
improvement in performance by new orientees, a smoother tran-
sition into the novice BMT nurse role, as well as a positive re-
sponse by experienced staff members regarding the performance of
novice BMT nurses.
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HUMAN HERPESVIRUS 6 (HHV6) INFECTION AND REACTIVATION IN
THE PEDIATRIC PATIENT AFTER ALLOGENEIC TRANSPLANTATION:
NURSING EDUCATION AND IMPLICATIONS FOR PATIENT CARE
Sickel, A.D., McConnell, C.L. The Children’s Hospital, Denver, CO.
Human herpesvirus 6 (HHV6) is a relatively mild viral infection
that causes roseola in infants and young children. In the immuno-
competent child, HHV6 is characterized by fevers and a rash and
generally resolves without medical treatment. In recent years, how-
ever, there has been an increase in detection of HHV6 in immu-
nocompromised patients, particularly in the pediatric bone marrow
transplantation population. The pediatric stem cell transplantation
nurse should be familiar with assessment, treatment options, and
diagnostic testing associated with HHV6 infection. This virus may
be a serious life-threatening pathogen in this patient population.
HHV6 infection may result from reactivation of latent virus in the
patient’s own blood or cerebrospinal ﬂuid, or it may be acquired
from the latent virus in the mononuclear cells of the donor’s
marrow after transplantation. Pretransplantation treatment regi-
mens, such as total body irradiation, antithymocyte globulin, and
CD3-speciﬁc monoclonal antibodies, may trigger viral reactivation
in the recipient. HHV6 has been associated with many symptoms,
including fevers, GVHD-like rash, invasive fungal infections, in-
terstitial pneumonia, graft failure, and encephalopathic symptoms.
The literature suggests that ganciclovir, phosphonoformate, and
cidofovir have an inhibitory effect against HHV6; however, there
are no conclusive studies on the efﬁcacy of these treatments.
Fortunately, very sensitive quantitative PCRs for HHV6 can be
used to monitor the response to antiviral therapy. Additionally, the
ability to give therapeutic doses of these drugs may be limited by
organ toxicity from previous nephrotoxic and marrow suppressive
medications. A case study will be used to describe the course of a
patient who becomes symptomatic from HHV6 reactivation after
an allogeneic cord blood transplantation.
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MANAGEMENT OF CYTOMEGALOVIRUS IN THE PEDIATRIC BONE MAR-
ROW/STEM CELL TRANSPLANTATION POPULATION
Stanton, T.J., Martin, P.L., Talbert, G. Duke University Medical
Center, Durham, NC.
Children undergoing stem cell and bone marrow transplantation
are at signiﬁcant risk for acquiring infections related to their
prolonged immunosuppression. Herpesviruses, in particular cyto-
megalovirus (CMV), continue to be a major complication for bone
marrow transplantation (BMT) patients, because this virus threat-
ens the survival both of the patient and the graft. Usually BMT
patients are either CMV before transplantation and have reacti-
vation of the infection once immunosuppression occurs, or they
acquire CMV through the transfusion of CMV blood products.
CMV usually attacks the lungs, causing CMV pneumonia which
occurs in approximately 20% of BMT patients. The liver, eyes, and
intestinal tract can also be affected by CMV infections. Early
detection and treatment of CMV is essential in decreasing mor-
bidity and mortality for the BMT patient. The Duke Pediatric
Bone Marrow/Stem Cell Transplant Program has developed an
effective approach for detecting and combating CMV infections.
The implementation of this approach has improved outcomes for
patients who develop CMV infections during the BMT process.
Further research and advances in pharmacology are imperative to
continuing to improve survival rates for BMT patients with active
CMV infections.
The purpose of this abstract is to detail the approach used by the
Duke Pediatric BMT/SCT program, including (1) identifying pa-
tients’ CMV status pretransplantation; (2) determining appropriate
prophylactic antiviral treatment based on patients’ renal function
and engraftment status; (3) monitoring all inpatients’ CMV status
weekly; (4) appropriately changing antiviral treatment based on
weekly CMV results; (5) adapting and altering treatment as needed
based on patients’ renal function and engraftment status; and (6)
continuing to monitor patients’ CMV status for 9 months post-
transplantation.
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CURRENT THERAPIES UTILIZED IN THE TREATMENT OF THE PEDIAT-
RIC NEUROBLASTOMA PATIENT
Gurganus, K.J., Frey, M.A., Driscoll, T. Duke University Medical
Center, Durham, NC.
Neuroblastoma is the most common tumor diagnosed in children
under age 1 year. This disease is a cancer of the sympathetic
nervous system that presents as a lump or mass in the abdomen or
around the spinal cord in the chest, neck, or pelvis. Neuroblastoma
is often present at birth, but often is not diagnosed until much later
when the child begins to manifest signs of the disease. Unfortu-
nately, the majority of cases (73%) of neuroblastoma have often
metastasized by the time of diagnosis. The most common present-
ing signs and symptoms include a lump or mass in the abdomen,
neck, or chest; bulging eyes, bone pain; petechiae; and weakness or
paralyisis. Diagnostic studies are completed, the disease is staged,
and the patient is referred for treatment. The prognosis and treat-
ment options depend on the patient’s age at diagnosis, stage of the
cancer, and histology of the tumor. Initial treatment options are
fairly standardized and include surgery and chemotherapy. The
purpose of this abstract is to describe the new treatment modalities
that are currently being used in children with this disease. The
Duke Pediatric Stem Cell Transplant Program is offering increas-
ing numbers of children new and experimental therapies used in
conjunction with autologous marrow transplantation. These ther-
apies include monoclonal antibodies; 1–131 mIBG, sometimes
done in conjunction with chemotherapy; tandem transplantation;
and fenretinide (a vitamin A derivative).
This poster will also include an overall summary of the disease,
treatment options, and statistics regarding survival rates and prog-
nosis. The individual treatments options, as well as nursing con-
siderations in the care of these children, will be presented.
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IMPROVING SKIN CARE OF THE PEDIATRIC BONE MARROW AND STEM
CELL TRANSPLANTATION PATIENT
Smith, M.L., Frey, M.A. Duke University Medical Center, Durham,
NC.
Infection remains the leading cause of mortality and morbidity in
the immunocompromised patient. The risk of infection is dramat-
ically increased when the body’s basic defenses are altered and lack
normal infection-ﬁghting capabilities. The skin is the largest organ
of the body and the most frequently affected. Patients undergoing
chemotherapy, radiation, and/or marrow ablation (bone marrow/
stem cell transplantation) are at even greater risk for life-threaten-
ing as a result of skin breakdown. Additional insults, such as
graft-versus-host disease, engraftment, respiratory and systemic
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